On October 22, HAB revised its Policy Clarification Notice (PCN) 16-02, Ryan White HIV/AIDS Program Services: Eligible Individuals & Allowable Uses of Funds, which was originally released in 2016. PCN…
On Monday, Health and Human Services Secretary Alex Azar announced a proposed rule that would require pharmaceutical manufacturers to disclose wholesale acquisition cost (“WAC”) prices in direct-to-consumer TV advertisements for…
Gilead Sciences Inc. announced that it would begin selling generic versions of the company’s two leading treatments for hepatitis C at substantially reduced prices. The generic versions of Epclusa and…
The House Energy and Commerce (E&C) Health Subcommittee held a hearing on the 340B program yesterday at 10 a.m. titled “Opportunities to Improve the 340B Drug Pricing Program.” The Subcommittee received testimony…
The 340B program was not a focus of today’s Senate HELP hearing on President Trump’s drug pricing blueprint entitled “American Patients First: The Trump Administration Blueprint to Lower Drug Prices…
The Senate Committee on Health, Education, Labor and Pensions (HELP) will hold a third hearing on the 340B program on June 19, 2018 at 10 a.m, Eastern time. The hearing…
The Senate Committee on Health, Education, Labor and Pensions (HELP), which has Senate jurisdiction over the 340B program, will hold a hearing titled “Perspectives on the 340B Drug Discount Program”…
On Thursday, December 21st, Rep. Larry Bucshon (R-IN) and Rep. Scott Peters (D-CA) introduced the 340B PAUSE Act, H.R. 4710, in the U.S. House of Representatives. The bill would “amend…
National Institutes of Health (NIH) Director Francis Collins stated yesterday that the agency does not have the authority to use its “march-in” rights as a tool to lower drug prices. …
Last week, President Trump declared the opioid epidemic a national public health emergency. The declaration allows federal agencies “to use every appropriate emergency authority to fight the opioid crisis.” The…